Why Is Catheter Precision Stock (VTAK) Up Today?

Catheter Precision VTAK +46.72% ▲ stock underwent a massive rally on Tuesday after the developer of electrophysiology products announced a merger agreement with Fly Flyte. Under the terms of this agreement, Catheter Precision will acquire the remaining 80.02% equity interest in Fly Flyte that it doesn’t own from Creatd CRTDD -7.50% ▼ .

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Catheter Precision said that with this acquisition, all operations, assets, and economics from Fly Flyte are fully consolidated within VTAK stock. The company said that it will consolidate Fly Flyte’s financial results into its own financial statements. The company also highlighted some benefits of the acquisition, including:

• Completion of a transformative business combination.

• Expansion into asset-backed transportation infrastructure.

• Aligning capital, governance, and growth strategy under a single structure.

• Positioning shareholders for long-term equity upside through disciplined fleet expansion.

David Jenkins, CEO and Chairman of Catheter Precision, said, “This transaction marks a defining inflection point for VTAK. We have transformed from a minority investor into the owner of an operating aviation business with tangible assets, certified infrastructure, and immediate revenue. Management believes full ownership of Flyte materially enhances VTAK’s long-term valuation profile by contributing consolidated revenues, asset backing, and the potential for substantial operating leverage.”

Catheter Precision Stock Movement Today

Catheter Precision stock was up 59.85% in pre-market trading on Tuesday, following a 2.84% fall yesterday. The shares have decreased 25.14% year-to-date and have fallen 81.1% over the past 12 months.

With today’s news came heavy trading of VTAK stock, as more than 25.7 million shares changed hands. That was well above the company’s three-month average daily trading volume of about 309,000 shares.

Is Catheter Precision Stock a Buy, Sell, or Hold?

Turning to Wall Street, traditional analyst coverage of Catheter Precision is lacking. Fortunately, TipRanks’ AI analyst Spark has it covered. Spark rates VTAK stock as Neutral with a $2 price target. It cites “weak financial performance driven by very large ongoing losses and significant cash burn, despite improving revenue” as reasons for this stance.

Disclaimer & DisclosureReport an Issue